See more : Kalray S.A. (ALKAL.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Burtech Acquisition Corp. (BRKH) Income Statement Analysis – Financial Results
- Synergy CHC Corp. (SNYR) Income Statement Analysis – Financial Results
- Applied BioCode Corporation (6598.TW) Income Statement Analysis – Financial Results
- ING Groep N.V. (INGVF) Income Statement Analysis – Financial Results
- I.C.P. Israel Citrus Plantations Ltd. (CTPL5.TA) Income Statement Analysis – Financial Results
Evolent Health, Inc. (EVH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.evolenthealth.com
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96B | 1.35B | 907.96M | 1.02B | 846.38M | 627.06M | 434.95M | 254.19M | 96.88M | 0.00 | 25.67M | 8.35M |
| Cost of Revenue | 1.50B | 1.04B | 657.55M | 701.37M | 513.06M | 327.83M | 269.35M | 155.18M | 57.40M | 0.00 | 30.02M | 11.27M |
| Gross Profit | 460.47M | 316.58M | 250.41M | 321.06M | 333.32M | 299.24M | 165.60M | 99.01M | 39.48M | 0.00 | -4.35M | -2.93M |
| Gross Profit Ratio | 23.45% | 23.42% | 27.58% | 31.40% | 39.38% | 47.72% | 38.07% | 38.95% | 40.75% | 0.00% | -16.93% | -35.08% |
| Research & Development | 0.00 | 27.00M | 15.50M | 15.10M | 19.80M | 18.20M | 17.20M | 11.10M | 5.80M | 0.00 | 2.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 358.11M | 269.27M | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 15.98M |
| Other Expenses | 173.57M | 67.20M | 60.04M | 61.48M | 60.91M | 109.00K | 171.00K | 4.00K | 7.17M | -25.25M | 1.00K | 0.00 |
| Operating Expenses | 531.68M | 336.46M | 279.54M | 372.03M | 453.73M | 350.82M | 238.04M | 177.92M | 82.45M | -25.25M | 16.81M | 16.69M |
| Cost & Expenses | 2.04B | 1.37B | 937.09M | 1.07B | 966.79M | 678.65M | 507.39M | 333.09M | 139.85M | -25.25M | 46.83M | 27.96M |
| Interest Income | 5.26M | 1.37M | 407.00K | 3.16M | 3.99M | 3.44M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K |
| Interest Expense | 54.21M | 15.57M | 25.43M | 28.34M | 14.53M | 5.48M | 3.64M | 723.00K | 293.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.42M | 90.25M | 60.04M | 60.84M | 66.64M | 44.52M | 32.37M | 17.22M | 7.17M | 0.00 | 1.21M | 114.00K |
| EBITDA | -24.79M | 43.75M | 55.66M | -241.38M | -245.95M | -4.15M | -40.40M | -220.31M | -31.51M | -25.25M | -20.35M | -19.51M |
| EBITDA Ratio | -1.26% | 0.54% | 9.94% | 2.31% | -7.73% | -1.32% | -9.20% | 38.10% | -464.44% | 0.00% | -257.85% | -233.70% |
| Operating Income | -71.21M | -59.84M | 30.25M | -37.88M | -120.41M | -47.48M | -72.84M | -237.42M | -42.97M | -25.25M | -21.16M | -19.62M |
| Operating Income Ratio | -3.63% | -4.43% | 3.33% | -3.71% | -14.23% | -7.57% | -16.75% | -93.40% | -44.36% | 0.00% | -82.41% | -235.07% |
| Total Other Income/Expenses | -131.19M | -65.72M | 12.61M | -67.69M | -18.23M | -6.67M | -3.56M | -114.00K | 386.26M | -25.25M | 41.19M | 19.00K |
| Income Before Tax | -202.41M | -62.08M | -29.80M | -337.80M | -327.12M | -54.15M | -76.40M | -237.53M | 343.29M | -25.25M | 20.03M | -19.60M |
| Income Before Tax Ratio | -10.31% | -4.59% | -3.28% | -33.04% | -38.65% | -8.64% | -17.57% | -93.45% | 354.35% | 0.00% | 78.03% | -234.84% |
| Income Tax Expense | -89.37M | -43.38M | 483.00K | -3.55M | -21.54M | 40.00K | -6.64M | -10.76M | 23.48M | 0.00 | 8.00K | 337.00K |
| Net Income | -113.04M | -18.70M | -30.28M | -334.25M | -305.58M | -52.66M | -60.67M | -159.74M | 332.49M | -25.25M | 20.02M | -19.26M |
| Net Income Ratio | -5.76% | -1.38% | -3.34% | -32.69% | -36.10% | -8.40% | -13.95% | -62.84% | 343.21% | 0.00% | 78.00% | -230.81% |
| EPS | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 13.14 | -0.66 | 0.06 | -1.13K |
| EPS Diluted | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 6.93 | -0.66 | 0.06 | -1.13K |
| Weighted Avg Shares Out | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.00M | 25.13M | 38.23M | 38.23M | 17.00K |
| Weighted Avg Shares Out (Dil) | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.03M | 46.14M | 38.23M | 38.23M | 17.00K |
Evolent Announces Third Quarter 2023 Results
Wall Street Analysts Think Evolent Health (EVH) Could Surge 76.14%: Read This Before Placing a Bet
Evolent to release third quarter financial results on Thursday, Nov. 2, 2023, and participate in upcoming investor conferences
Wall Street Analysts Believe Evolent Health (EVH) Could Rally 77.45%: Here's is How to Trade
Evolent Health (EVH) Moves to Buy: Rationale Behind the Upgrade
A First Evaluation On Evolent Health
Evolent saves Medicare more than $55 million through its Medicare Shared Savings Program ACO
Evolent Health to Participate in Upcoming Conferences
Evolent Health, Inc. (EVH) Q2 2023 Earnings Call Transcript
Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports